ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,176.23
-0.02%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immutep Limited (PBMD)

  7. Immutep Limited (PBMD) Noticias

PBMD

Immutep Limited (PBMD)

Immutep Limited
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PBMD
FechaHoraFuenteTítuloSímboloCompañía
23/02/201805:09Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PBMDImmutep Limited
27/11/201718:12GlobeNewswire Inc.Prima BioMed Becomes ImmutepNASDAQ:PBMDImmutep Limited
21/11/201717:07GlobeNewswire Inc.Prima Secures European Patent Grant for Lead Product IMP321 in CancerNASDAQ:PBMDImmutep Limited
20/11/201700:59GlobeNewswire Inc.Prima BioMed Changes Its Name to Immutep LtdNASDAQ:PBMDImmutep Limited
15/11/201702:11GlobeNewswire Inc.Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDANASDAQ:PBMDImmutep Limited
08/11/201716:45GlobeNewswire Inc.New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual...NASDAQ:PBMDImmutep Limited
03/11/201705:01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PBMDImmutep Limited
31/10/201718:15GlobeNewswire Inc.Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017NASDAQ:PBMDImmutep Limited
19/10/201722:23GlobeNewswire Inc.Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017NASDAQ:PBMDImmutep Limited
19/10/201715:41Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:PBMDImmutep Limited
19/10/201715:39Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PBMDImmutep Limited
16/10/201723:37GlobeNewswire Inc.IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual MeetingNASDAQ:PBMDImmutep Limited
08/09/201700:25GlobeNewswire Inc.Prima Secures Japanese Patent Grant for IMP731 AntibodyNASDAQ:PBMDImmutep Limited
05/09/201702:54GlobeNewswire Inc.Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious DiseaseNASDAQ:PBMDImmutep Limited
30/08/201705:07GlobeNewswire Inc.Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research ProjectNASDAQ:PBMDImmutep Limited
20/08/201719:07GlobeNewswire Inc.Prima BioMed Appoints Non-Executive Director to the BoardNASDAQ:PBMDImmutep Limited
15/08/201721:01GlobeNewswire Inc.Prima BioMed Receives A $1.3 Million Tax Refund From French GovernmentNASDAQ:PBMDImmutep Limited
17/07/201719:33GlobeNewswire Inc.Financial Update 2H17NASDAQ:PBMDImmutep Limited
16/07/201719:37GlobeNewswire Inc.Prima BioMed Announces Second Milestone Payment for IMP701 ProgramNASDAQ:PBMDImmutep Limited
14/07/201712:45Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:PBMDImmutep Limited
09/07/201722:46GlobeNewswire Inc.Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical TrialNASDAQ:PBMDImmutep Limited
30/06/201716:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PBMDImmutep Limited
29/06/201710:39GlobeNewswire Inc.Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary SharesNASDAQ:PBMDImmutep Limited
28/06/201716:22Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:PBMDImmutep Limited
26/06/201705:33GlobeNewswire Inc.Operational UpdateNASDAQ:PBMDImmutep Limited
04/06/201719:36GlobeNewswire Inc.LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical TrialNASDAQ:PBMDImmutep Limited
31/05/201719:54GlobeNewswire Inc.Prima BioMed Announces Formation of Clinical Advisory BoardNASDAQ:PBMDImmutep Limited
17/05/201719:27GlobeNewswire Inc.Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO ConferenceNASDAQ:PBMDImmutep Limited
18/04/201720:45GlobeNewswire Inc.Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma TrialNASDAQ:PBMDImmutep Limited
12/04/201703:25GlobeNewswire Inc.Prima BioMed Receives A$492,144 Tax Refund From Australian GovernmentNASDAQ:PBMDImmutep Limited
 Showing the most relevant articles for your search:NASDAQ:PBMD

Su Consulta Reciente

SPI
SP500
S&P 500
NYSE
MCD
McDonalds
FX
EURUSD
Euro vs US Dollar
PM
XAUUSD
Gold vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
GOOGL
Alphabet
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
NASDAQ
TSLA
Tesla
NYSE
CVX
Chevron
NYSE
AXP
American Express
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
RHHBY
Roche (QX)
USOTC
BNPQY
BNP Paribas (QX)
CCOM
OILBRENT
Brent Oil
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados